Jeito Capital announces appointment of new Partner Investor Ksenija Pavletic

Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the promotion of Ksenija Pavletic to Partner Investor.

As part of the Jeito founding team with over 25 years of international experience in the pharmaceutical and biotech sector, Ksenija contributed to Jeito’s development as Chief Commercial Officer (“CCO”). She has been promoted to help lead Jeito’s strong growth plans.

As with all Jeito employees, she has coupled her expertise in investment strategies with a deep and exceptional healthcare knowledge, especially in the companies’ building capabilities.

Prior to joining Jeito, she was CEO of Swiss-based, reproductive health pharma company PregLem SA where she helped lead the company’s rapid expansion (2007-2021).
At PregLem, she brought the company from a clinical to a commercially successful operation. She built fully fledged European commercial organization (300 people), launched several products, led the negotiations of several licensing deals which expanded PregLem’s portfolio, acquired a company and delivered cumulative sales of over €260 million within five years of the lead product launch. PregLem, had a successful exit for CHF445 million three years after the inception.

Prior to PregLem, Ksenija worked for eleven years with Serono (then Merck Serono) (1996-2007) in various regional and global business, sales and marketing positions.

Ksenija also offers her strong commercial and operational expertise to Jeito’s portfolio companies and has notably been instrumental in the development of Jeito’s portfolio company for which she acted as CEO since 2022: Advesya, a pioneering biopharma company that emerges today from stealth mode (see press release). Advesya has developed a breakthrough technology that address the medical needs in patients with refractory myeloid cancers, with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments.

Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said “I founded Jeito Capital with the objective to build and grow European biopharma champions with global ambitions thanks to the support of an integrated Jeito team of talented experts joining forces to accelerate the access to innovative therapies for patients. Ksenija, as a founding member and today as a Partner, is instrumental to this collective success. I thank her and all Jeito teams for their steady commitment and spirit of excellence.”

Commenting on her appointment, Ksenija Pavletic, Partner Investor, added “I am delighted to use this opportunity to promote growth for Jeito and our portfolio companies, especially with the official launch of Advesya. Since the founding of Jeito, and under the leadership of Rafaèle, the team and I have pushed for innovation in all areas of the biopharma sector. I look forward to helping implement our vision in this next chapter and continuing to support the team and our portfolio companies as they continue to scale to create life changing solutions for patients.”

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

For more information, please visit or follow us on Twitter or LinkedIn.

For further information please contact:

Jeito Capital
Rafaèle Tordjman
Jessica Fadel, EA
Tel: +33 6 33 44 25 47

H/Advisors Maitland
David Stürken
Tel: +44 (0) 799 059 5913